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Abstract
Background: Central to the pathology of coronary heart disease is the accumulation of lipids, cholesterol and triglycerides,
within the intima of arterial blood vessels. The search for drugs to treat dislipidemia, remains a major pharmaceutical focus.
In this study, we evaluated the hypolipidemic properties of the essential oil from Chios mastic gum (MGO).
Methodology/Principal Findings: The hypolipidemic effect of MGO was investigated in naı ¨ve as well as in rats susceptible
to detergent-induced hyperlipidemia. Serum cholesterol and triglycerides were determined using commercial kits. HMG-
CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase activity was measured in HepG2 cell extracts using a radioactive
assay; cellular cholesterol and cholesterol esters were assessed using gas chromatography. MGO administration into naı ¨ve
rats resulted in a dose-dependent reduction in the constitutive synthesis of serum cholesterol and triglycerides. In
hyperlipidemic rats, MGO treatment had also a strong hypolipidemic effect. By testing various components of MGO, we
show for the first time that the hypolipidemic action is associated with camphene. Administration of camphene at a dose of
30 mg/gr of body weight in hyperlipidemic rats resulted in a 54.5% reduction of total cholesterol (p,0.001), 54% of Low
Density Lipoprotein (LDL)-cholesterol (p,0.001) and 34.5% of triglycerides (p,0.001). Treatment of HepG2 cells with
camphene led to a decrease in cellular cholesterol content to the same extend as mevinolin, a known HMG-CoA reductase
inhibitor. The hypolipidemic action of camphene is independent of HMG-CoA reductase activity, suggesting that its
hypocholesterolemic and hypotriglyceridemic effects are associated with a mechanism of action different than that of
statins.
Conclusions: Given the critical role that the control of hyperlipidemia plays in cardiovascular disease, the results of our
study provide insights into the use of camphene as an alternative lipid lowering agent and merits further evaluation.
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Introduction
High levels of plasma cholesterol and triglycerides are strongly
associated with the development of atherosclerosis and coronary
heart disease [1–4] and clinical trials designed to reduce serum
cholesterol levels by diet or pharmacological means have shown to
lead to a reduction in the incidence of this disease [5]. One of the
most effective ways of reducing circulating cholesterol levels is to
inhibit endogenous cholesterol biosynthesis in the liver as in
humans 50% or more of total body cholesterol is derived from de
novo synthesis [6]. Further, it has been demonstrated that statins
are the predominant inhibitors of HMG-CoA reductase [7] the
enzyme that catalyzes the rate determining step of cholesterol
biosynthesis. These drugs effectively lower LDL-cholesterol in
humans [8] and reduce mortality and morbidity from coronary
artery disease [9–12]. However, despite the success of treatment by
statins there is a need for new therapies to reduce LDL-cholesterol,
since some patients do not tolerate statins well and more
importantly many patients under statin treatment alone do not
achieve the LDL-cholesterol goal according to guidelines suggest-
ed by the National Institutes of Health, USA. Recently, several
efforts aim to develop more effective hypolipidemic drugs that
originate from natural agents.
Chios mastic gum (MG) is a resin produced by the plant Pistacia
lentiscus L. var Chia. MG is produced almost exclusively by plants
grown in the southern part of island of Chios in Greece. Repeated
attempts have shown that P. lentiscus can be cultivated in other
parts of the world, but the plant will not produce resin. Since 3000
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cooking, preparation of beverages, cosmetics, and paints, and
treatment of gastric ailments. MG is used to extract mastic gum
essential oil (MGO). Since 1997, MG and MGO have been
characterized as Products of Protected Origin by the European
Union, and rediscovered for their numerous and diverse
biomedical and pharmacological properties including, (i) eradica-
tion of bacteria and fungi that may cause peptic ulcers, tooth
plaque formation and malodor of the mouth and saliva [13–24] (ii)
amelioration or dramatic reduction of symptoms of auto-immune
diseases by inhibiting production of pro-inflammatory substances
by activated macrophages, production of cytokines by peripheral
blood mononuclear cells in patients with active Crohn’s disease,
and suppression of production of inflammatory cytokines and
chemokines in a mouse asthma model [25–28]; (iii) anti-
inflammatory and anti-oxidant properties [25–31]; (iv) protection
of the cardiovascular system by effectively lowering the levels of
serum cholesterol and protection of LDL from oxidation [30,31];
(v) antitumor growth activities against several cancer types
(leukemia, prostate, colon, lung and melanoma cancer) [32–40]
and (vi) improvement of symptoms in patients with functional
dyspepsia [41].
MG and MGO are highly insoluble in water, but somewhat
soluble in different organic solvents. Their chemical composition
has been analyzed, and several constituents have been isolated and
identified in various fractions [15,17,20,42–45]. In general, of the
69 MGO constituents, 61 have been identified. Six constituents b-
caryophyllene, a-pinene, b-pinene, camphene, b-myrcene, and
linalool comprise 65% to 80% of the weight of all product
extracted. The same major constituents were found in both MG
and MGO, but MG proved to be more difficult to handle than
MGO [17]. In this report, we present experimental evidence that
MGO can prevent hyperlipidemia, that is, prevent increase of total
cholesterol, LDL-cholesterol and triglycerides following their
induction in a rat model. The effects of various MGO components
on the content of plasma lipids in hyperlipidemic rats were also
investigated in order to determine the active hypolipidemic
component. The hypolipidemic activity of MGO was unequivo-
cally associated with camphene and it was also demonstrated that
the lipid-lowering effect of this monoterpene proves to be dose-
dependent. We also report that the hypolipidemic activity of
camphene in hepatic cells is mediated via a metabolic process
distinctly different than the process of inhibition of HMG-CoA
reductase induced by statins. This study also compares the efficacy
of camphene in lowering intracellular cholesterol and cholesterol
ester levels with that of mevinolin, a potent lipid lowering drug.
Treatment with camphene exhibited no cytotoxicity in human
hepatic cells. Thus, camphene may develop as an alternative lipid
lowering agent, whereas further investigation is warranted in order
to elucidate its molecular mechanism of action.
Methods
Materials
MGO was obtained by steam distillation and was kindly
donated by the Association of Chios Mastic Gum Producers
(Chios, Greece). The MGO constituents, a-pinene, b-pinene,
myrcene, linalool, b-caryophyllene and camphene, mevinolin, the
detergents, Triton WR-1339 and Tween-80, and the MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were
from Sigma-Aldrich (St. Louis, MO). Triton WR-1339 was used
for induction of hyperlipidemia, and Tween-80 as emulsifier.
[
14C]HMG-CoA (10 mCi), [2-
14C] acetic acid sodium salt
(250 mCi) and [1-
14C] oleic acid (50 mCi) were from Amersham
Biosciences (UK Ltd). Resin AG 1-X8 formate-form and reagents
for protein determination were obtained from BioRad (Berkeley,
CA, USA). The enzymatic determination of total cholesterol,
LDL-cholesterol and triglycerides in plasma were assayed using
commercially available kits obtained from Randox laboratories
Ltd (Antrim, UK).Reagents for protein determination were from
Bio-Rad. The human hepatic cell line, HepG2, was purchased
from ATCC (Manassas, VA, USA). Cell culture medium,
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum
(FBS), and antibiotics, penicillin and streptomycin, were from
Gibco BRL Life Technologies (Gaithersburg, MD, USA).
Lipoprotein-deficient serum (LPDS) was obtained from Autogen
Bioclear UK Ltd (Wilts, UK).
Ethics statement
Animals received proper care in compliance with the ‘‘Guide-
lines for the Care and Use of Laboratory Animals’’ published by
the Greek Government (160/1991) based on EU regulations (86/
609) All experiments were reviewed and approved by the
Institutional Animal Care and Use Committee at Aristotle
University of Thessaloniki (protocol #13/16588).
Animal experimentation
Female Fisher-344 rats, 2–4 months old and weighing 180–
200 g each were used in this study. The animals were housed
under standard laboratory conditions (18uC–20uC, 12 h light and
dark cycle) and received a diet of commercial food pellets and tap
water ad libitum. Triton WR-1339 was stirred in KCl 1.15% until
dissolved and doses of 200 mg/kg were injected intraperitoneally
(ip) during about 25 sec with the aid of ether anaesthesia. MGO
and MGO components were administered intraperitoneally (ip)
into the rats at the desired doses (depending on the study) in 1 ml
of a carrier consisting of 10% Tween-80 (v/v) in normal saline.
Control animals received 1 ml of carrier alone (placebo). Triton
WR-1339 was administered ip to rats 1 h after ip administration of
the tested compound dissolved in carrier. Rats were deprived of
food prior to Triton WR-1339 administration, but they were
allowed free access to drinking water. Each animal group (for each
compound treatment) consisted of six rats. For studies in
hyperlipidemic rats, one group received 1 ml carrier and served
as control #1 (placebo); the second group of animals received
Triton alone and served as control #2 for hyperlipidemia
induction; and the third animal group received treatment with
various MGO constituents in 1 ml carrier one hour prior to
administration of Triton WR-1339. The hypolipidemic activity of
MGO and its constituents was concluded by comparing the lipid
contents in plasma from animals treated with Triton alone and in
plasma from animals treated with Triton and MGO or MGO
constituents. Twenty-four hours later, blood was collected from
the hearts of animals in heparinised tubes, centrifuged to obtain
plasma and stored at 280uC. The levels of total cholesterol, LDL-
cholesterol, and triglycerides in plasma were measured using
commercially available diagnostic kits according to instructions
provided by the manufacturer.
Cell culture
HepG2 cells were cultured in DMEM supplemented with 10%
FBS, penicillin (100 units/ml) and streptomycin (0.25 mg/ml) at
37uC in a humidified atmosphere of 5% CO2. The cell cultures
were routinely passaged, while growing exponentially. The test
compounds were dissolved in absolute ethanol prior to appropriate
dilution with cell culture medium so that the final ethanol
concentration never exceeded 0.5% (vol/vol) in the culture. Cell
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dye method and by the Bio-Rad protein assay, respectively.
Cell treatment with various compounds and preparation
of cell extracts
On day 0, 3610
5 cells were seeded in cell culture dishes (60-mm
diameter) in DMEM containing 10% FBS. On day 3 or 4, the
medium was replaced with FBS-containing fresh medium, which
was subsequently replaced on day 6 with DMEM containing 10%
LPDS, instead of FBS, followed by incubation for 24 h. On day 7,
the cells were pre-incubated for 18 h with camphene and
mevinolin in fresh DMEM containing LPDS. Following incuba-
tion, the cells were washed twice with DMEM and incubated in
DMEM for another 15 min to remove intracellular material.
Subsequently, the cells were washed three times with cold PBS,
pH 7.4, and detached from the substrate with the aid of a rubber
policeman. PBS containing the detached cells was centrifuged at
20006g for 5 min at 4uC, the clarified supernatant was discarded,
and the cell pellet was stored at 280uC until used.
Cell extracts were prepared according to a published procedure
[46]. Briefly, the cell pellet was suspended in 100 ml of a lysis buffer
containing 50 mM imidazole, pH 7.4, 250 mM NaCl, 2 mM
EGTA, 1 mM EDTA, 5 mM dithiothreitol, 50 mM leupeptine
and 0.25% Brij 97. After incubation for 30 min at 37uC the
homogenate was centrifuged for 10 min at 120006ga t4 uC and
aliquots of the supernatant were used to assay for HMG-CoA
reductase activity. The cellular protein content was determined
using the Bio-Rad protein assay.
MTT assay
Cell viability of HepG2 cells was evaluated using the MTT
assay [47]. Briefly, cells were seeded into 96-well plate with an
initial density of 1610
5 cells per well. After 24 h of incubation
various concentrations of camphene were added. Each treatment
was performed in triplicates. Cells were incubated for another
24 h in a 5% CO2 incubator at 37uC. Four hours prior to
termination of the incubation, medium was discarded and 100 ml
of MTT (1 mg/ml in PBS) were added to each well, to allow the
formation of formazan crystals. Then the medium was discarded,
100 ml/well of DMSO was added to dissolve the formazan
crystals, and the plates were incubated for 10 min at room
temperature. The optical absorbance value at 540 nm was
detected with a microplate reader. The absorbance value that
was determined for cells cultured in complete media without
camphene corresponded to 100% viability.
HMG-CoA reductase activity assay
Twenty-ml of the cell extract (see above) were vigorously mixed
with 30 ml of cell lysis buffer and then incubated at 37uC for
15 min. The reaction was initiated by the addition of 25 mlo fa
solution containing 50 mM imidazole, pH 7.4, 250 mM NaCl,
2 mM EGTA, 76 mM EDTA, 5 mM DTT, 90 mM glucose-6-
phosphate, 0.75 units of glucose-6-phosphate dehydrogenase,
2.5 mM NADP
+ and 30 mM[
14C]HMG-CoA (0.02 mCi). Con-
trols consisted of 50 ml lysis buffer alone. The samples were
incubated for 60 min at 37uC and 25 ml of 5 M HCl were added
to terminate the reaction. After standing for 30 min at 37uCt o
allow for lactonization of the mevalonic acid the samples were
centrifuged for 3 min at 100006g to pellet denatured protein.
[
14C] mevalonolactone was separated from [
14C]HMG-CoA on a
small column packed with ion exchange resin (AG 1-X8 formate-
form). The column was made up in water and the sample was
eluted 36 with 1 ml of water. The eluates were collected and
radioactivity was measured in a liquid scintillation counter
(Quicksafe A, Zinsser Analytic). Enzyme activity was expressed
in counts per minute.
Determination of cell cholesterol
On day 7 (see: Treatment of HepG2 cells), the cells were pre-
incubated for 1 h and 18 h with camphene and mevinolin in
DMEM containing 10% LPDS. Following incubation the cells
were washed 36with cold PBS, detached with the aid of a rubber
policeman and collected in 1 ml of PBS. The protein content was
determined and lipids were extracted by the method of Bligh and
Dyer [48]. Briefly, appropriate volumes of chloroform and
methanol were added to cells suspended in 1 ml of PBS in order
to obtain a one-phase system consisting of CHCl3/CH3OH/H2O
(1:2:0.8, v/v/v). After vigorous mixing, the appropriate volumes of
chloroform and water were added to obtain a two-phase system
CHCl3/CH3OH/H2O at 1:1:0.9 ratios (v/v/v) followed by
another vigorous mixing. Then, the mixture was allowed to
equilibrate for 30 min at 220uC until the two phases were
separated. The chloroform phase containing total lipids was
removed and evaporated under nitrogen stream, then the lipids
were dissolved in CHCl3/CH3OH (2:1, v/v), and cholesterol was
determined by gas chromatography (Hewlett Packard 5890 Series
II). One-hundred mg of cholestane in chloroform was added, as an
internal standard, to a volume of cell suspension containing 1 mg
of protein. The temperature program was started at 180uC,
increased to 300uC at a rate of 15uC/min and maintained at
300uC for 12 min.
Cholesterol ester determination
Lipids were extracted by the method of Bligh and Dyer [48].
Cholesterol ester in chloroform was added as an internal standard.
The lipids were dissolved in a mixture of CHCl3/CH3OH (2:1, v/
v) and separated by Thin Layer Chromatography (TLC) using
hexane/diethylether/acetic acid as the developing system. Lipid
spots were located under ultraviolet light after spraying with a
solution of dichlorofluorescein in ethanol, and each spot was
excised and transmethylated in methanolic sodium methoxide
followed by treatment with methanolic boron trifluoride. The
cholesterol esters thus produced were extracted with hexane and
separated in a gas chromatograph. The temperature program
started at 160uC and increased to 270uC at a rate of 5uC/min.
Statistical analysis
Mean and standard error of means are reported. Significant
differences between values of treated and control groups were
determined using the unpaired Student’s t test (two-tailed) or the
Student-Newmann-Keuls test.
Results
Effect of MGO on plasma lipid levels in naı ¨ve animals
We initially determined whether MGO could affect the lipid
contents in the plasma of naı ¨ve rats prior to induction of
hyperlipidemia. For this, we treated naı ¨ve animals with two
different MGO doses, 2.5% and 4%, and then compared the lipid
contents in the plasma before and after MGO administration.
After treatment with 2.5% MGO there were decreases in total
cholesterol, LDL-cholesterol, and triglycerides by 29%, 23.9%,
and 21.2%, respectively, whereas, the 4% MGO dose resulted in
reductions of 53.6%, 45.2% and 30.6% in the contents of total
cholesterol, LDL-cholesterol and triglycerides, respectively
(Table 1). These results indicated that the 4% MGO dose was
more effective than the 2.5% dose in reducing the lipid contents in
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reduction could be dependent on the MGO dose administered
into the animals. Furthermore, MGO administration did not affect
food intake.
Hypolipidemic activity of MGO on plasma lipids in
hyperlipidemic rats
The effect of MGO on plasma cholesterol and triglyceride levels
was assessed in a rat model in which the circulating levels of total
cholesterol, LDL-cholesterol and triglycerides were substantially
increased following administration of the detergent, Triton WR-
1339. This compound has been widely used for induction of acute
hyperlipidemia in several animal models [49–51] and for screening
natural and chemical hypolipidemic drugs [52,53]. The rationale
of the experiments with hyperlipidemic rats is described in the
methods section. MGO was administered at doses of 2.5%, 4%,
5% and 7.5% (v/v). As seen in Table 2, column A: placebo, the
content of each plasma lipid category was similar in all control
(placebo) animals, ranging from about 53 to 61 mg/dl for total
cholesterol, 9 to 10 mg/dl for LDL-cholesterol, and 140–144 mg/
dl for triglycerides. Administration of Triton WR-1339 caused a
dramatic increase in the content of plasma lipids ranging from 416
to 628 mg/dl for total cholesterol, 119 to 270 mg/dl for LDL-
cholesterol, and 2752 to 4673 mg/dl for triglycerides (Table 2,
column B: Triton WR-1339). However, the induction in lipid
content was lower in animals which had received various MGO
doses prior to Triton administration. Thus, in hyperlipidemic
animals treated with various MGO doses, the plasma contents
were 168 to 375 mg/dl for total cholesterol, 38 to 130 mg/dl for
LDL-cholesterol, and 1088 to 2571 mg/dl for triglycerides,
respectively (Table 2, column C: MGO+Triton WR-1339).
Table 2 shows that plasma lipid contents were not significantly
different between hyperlipidemic animals and hyperlipidemic
animals that had received a 2.5% MGO (p.0.05). In contrast,
significant decreases were observed in total cholesterol (55.8%),
LDL-cholesterol (51.8%) and triglycerides (50.1%) in hyperlipid-
emic animals receiving a 4% MGO dose with p,0.001. Moreover,
rats that received a 5% or 7.5% MGO dose exhibited further
reductions in the various lipid contents with p,0.001 (Table 2).
Thus, it appears that the most effective inhibition occurred when a
4% MGO dose was administered in the rats, and that MGO doses
above 4% resulted in a small additional or no further inhibition of
lipid contents. Taken these results collectively we concluded that
4% was the optimal MGO dose, since it was the lowest one that
decreased plasma lipids to more than 50 percent.
Effect of various MGO constituents on plasma lipids in
hyperlipidemic rats
As mentioned in the Introduction section the chemical
composition of MG, MGO and resins extracted from the insect
galls on P. lentiscus have been analyzed, and several constituents
have been isolated and identified in various fractions. More than
80% of MGO consists of 66.48% a-pinene, 3.29% b-pinene,
8.34% myrcene, 2.84% linalool, 2.04% b-caryophyllene and
0.83% camphene [42]. To examine the effect of major MGO
constituents, each constituent was administered separately to rats
at a dose identical to that contained in the optimal MGO dose
(4%). No significant changes were measured in the plasma lipids of
hyperlipidemic animals treated with a-pinene, b-pinene, myrcene,
linalool and b-caryophyllene, whereas, a significant reduction in
lipids was observed in the plasma of the animals treated with
camphene (p,0.001; Table 3). Thus, in the camphene treated rats
the total cholesterol content was decreased 19.4%, LDL-
cholesterol by 18.1% and triglycerides by 22.9% (Table 3). These
results indicated that the lipid-lowering activity of MGO was
associated with one of its components namely camphene.
The hypolipidemic effect of MGO is unequivocally
associated with camphene
To further assure that the hypolipidemic activity of MGO is
linked to the presence of camphene, we carried out an experiment
in which the rats were administered two mixtures, A and B, of
MGO constituents. Mixture A consisted of a-pinene, b-pinene,
myrcene, linalool, and b-caryophyllene, and Mixture B consisted
of Mixture A+camphene. Mixture A and Mixture B were
prepared so that the dose of each constituent was equal to that
contained in 4% MGO. As it is shown in Table 4, treatment with
Mixture A (without camphene) had no significant effect on plasma
lipids (p.0.05), whereas, rats treated with Mixture B (containing
camphene) resulted in a significant decrease in plasma lipids.
Specifically, administration of mixture B to hyperlipidemic rats
resulted in total cholesterol reduction by 40.4%, LDL-cholesterol
reduction by 61.1%, and triglyceride reduction by 54.4%, when
compared to hyperlipidemic rats treated with Triton WR-1339
Table 1. Effect of various MGO concentrations on contents of total cholesterol, LDL-cholesterol and triglycerides in the plasma of
naı ¨ve rats (without induction of hyperlipidemia).
Rat group
MGO dose Plasma lipid content Placebo +MGO Lipid content decrease
after MGO treatment (%)
2.5% Total cholesterol 57.364.4 40.764.2 (,0.0001) 29.0
2.5% LDL cholesterol 18.561.6 14.061.0 (0.0002) 23.9
2.5% Triglycerides 85.5615.0 67.5615.7 (0.07) 21.1
4% Total cholesterol 69.368.5 32.166.6 (,0.0001) 53.6
4% LDL cholesterol 13.262.2 7.361.4 (,0.0003) 45.2
4% Triglycerides 114.8614.4 79.6614.20 (0017) 30.6
The placebo (control) group was administered 1 ml carrier alone. The MGO treated group received a dose of MGO cocktail. The injected cocktails of different doses of
MGO consisted of: 2.5% or 4% MGO (v/v) in 1 ml carrier. Twenty-four h later, blood was collected from the hearts of animals in heparinized tubes and plasma samples
were prepared and assayed for total cholesterol, LDL-cholesterol, and triglycerides. The values represent mean 6 SD of six rats. p-values of unpaired Student’s t test
(two-tailed) are shown in parentheses (MGO-treated rat groups vs placebo-receiving group).
doi:10.1371/journal.pone.0020516.t001
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indeed the MGO constituent exhibiting the hypolipidemic activity.
Lipid-lowering effects of various camphene
concentrations in hyperlipidemic rats
After determining that camphene was the MGO constituent
exhibiting anti-hyperlipidemic activity, we investigated whether
this activity was dependent on the camphene concentration. For
this study, various camphene doses were injected into rats one
hour prior to injection of the hyperlipidemia-inducing agent,
Triton WR-1339. The camphene doses were 1.5, 7.5 and 30 mg/g
of body weight. Control animals received Triton WR-1339 alone.
As previously observed, injection of Triton WR-1339 resulted in
dramatic increases in total cholesterol, LDL-cholesterol and
triglycerides as shown in Table 5 (compare column B to column
A). However, the Triton-induced increase in lipid content was
attenuated in the rats that had received camphene prior to Triton
injection (compare column C to column B). Further, the extent of
attenuation of the lipid content increase was positively correlated
with the camphene dose. Thus, the percentage of attenuation for
each lipid category was minimal in rats injected with a 1.5 mg/g
dose, and maximal in rats injected with a 30 mg/g dose (Table 5).
Further, the 30 mg/g dose resulted in 50% or higher attenuation in
the contents of total cholesterol (54.5%) and LDL-cholesterol
(54.0%). Also, the 30 mg/g dose resulted in a dramatic attenuation
of Triton-induced increase in triglycerides content (34.5%). It is
apparent that a camphene dose of 7.5 mg/g body weight was the
lowest dose used to accomplish the maximal inhibition in LDL-
cholesterol and triglyceride contents. However, camphene doses
higher than 7.5 mg/g were required to accomplish extensive
inhibition of total cholesterol content. A possible explanation is
that total cholesterol consists of lipid forms, in addition to
LDL-cholesterol, which are not affected by camphene. It should
be noted that this higher camphene dose (30 mg/g) corresponds to
a 20-fold higher dose of camphene that is present at the 4% MGO
dose. Therefore, the anti-hyperlipidemic effect of camphene
appears to be dose-dependent with more than 50% of its
effectiveness exhibited when a 7.5 mg/g dose was used. Finally,
no toxicity was observed in the animals even after receiving the
highest camphene dose of 30 mg/g (or 30 mg/kg) of body weight.
Apparently, this dose was well-tolerated and it was much lower
than the reported camphene LD50 for rats which was shown to be
higher than 5 g/kg of body weight (CAS No. 79-92-5: Screening
information Data Set (SIDS) of OECD High Volume Chemicals
Programme, 1993).
Effect of camphene on intracellular cholesterol content
The in vivo studies demonstrated the hypolipidemic activity of
camphene. It is well known that the commonly used drugs, statins,
lower hyperlipidemia by inhibiting HMG-CoA reductase, the
cellular enzyme required for cholesterol biosynthesis [8]. To study
the effect of camphene on cholesterol biosynthesis, the HepG2 cell
line was used as a model. This cell line has been widely used as an
in vitro model to delineate the effect of various lipid regulating
agents on lipid metabolism. The effect of camphene on cholesterol
biosynthesis was compared with the potent lipid lowering drug,
mevinolin. Mevinolin is a commercially available statin, a member
of the drug family systemically administered to hyperlipidemic
individuals to inhibit HMG-CoA reductase and consequently
lower the amounts of blood circulating total cholesterol, LDL-
cholesterol and triglycerides [9,10]. The concentration of
mevinolin resulting in maximal inhibition of cholesterol biosyn-
thesis is 37 mM in HepG2 cells [54]. We compared the effects of
camphene and mevinolin on cholesterol biosynthesis in HepG2
Table 2. Effect of various MGO concentrations on contents of total cholesterol, LDL- cholesterol and triglycerides in the plasma of
Triton WR-1339 treated rats.
Rat Group
MGO Plasma lipid (A) (B) (C) Percentage of lipid
dose content(mg/dl) Placebo +Triton WR-1339 +MGO decrease in rat group (C)
+Triton WR-1339 compared to rat group (B)
2.5% Total cholesterol 57.367.0 416.0653.0 375.4631.4
ns 9.75
2.5% LDL-cholesterol 9.262.0 119.2622.9 108.5616.1
ns 9.0
2.5% Triglycerides 143.5632.8 2752.46580.7 2571.46469.4
ns 6.6
4% Total cholesterol 60.569.3 483.5637.6 213.5618.5
*** 55.8
4% LDL-cholesterol 10.361.9 270.6623.9 130.3621.1
*** 51.8
4% Triglycerides 142.0628.5 4673.36400.7 2331.36252.4
*** 50.1
5% Total cholesterol 52.863.5 628.4632.1 256.5629.0
*** 59.2
5% LDL-cholesterol 10.260.9 219.6622.9 64.569.0
*** 70.6
5% Triglycerides 39.8610.4 4545654.2 2043.26102.0
*** 55.0
7.5% Total cholesterol 58.667.6 420.6627.8 168.6620.5
*** 59.9
7.5% LDL-cholesterol 10.162.8 138.468.6 38.063.7
*** 72.5
7.5% Triglycerides 139.8628.0 3146.96294.4 1088.26144.5
*** 65.4
The placebo (control) group (A) was administered 1 ml carrier alone. The Triton WR-1339 group (B) was administered 1 ml carrier and one hour later 1 ml of Triton WR-
1339 (200 mg/kg). The MGO-treated group (C) received a dose of MGO and one h later a single dose of Triton WR-1339. MGO was administered at 2.5%, 4%, 5% and
7.5% (v/v) in 1 ml carrier. Controls and MGO were injected intraperitoneally. Twenty-four h later, blood was collected from the hearts of animals in heparinized tubes
and plasma samples were prepared and assayed for total cholesterol, LDL-cholesterol, and triglycerides. The values represent mean 6 SD of six rats. Significantly
different values were obtained from MGO-treated rats as compared to Triton WR-1339 treated rats with p,0.001 (***) by the Student-Newmann-Keuls test; ns, non
significant (p.0.05).
doi:10.1371/journal.pone.0020516.t002
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After incubation for 1 h and 18 h with camphene (37 mM) and
mevinolin (37 mM), lipids were extracted and total cholesterol was
determined by gas chromatography. After 1 h, the cholesterol
content was decreased by 20% (p,0.001) and 20.7% (p,0.01) in
cells incubated with camphene and mevinolin, respectively, as
compared to control cells exposed to LPDS alone (Figure 1).
Further, incubation of HepG2 cells camphene and mevinolin for
Table 3. Effect of various MGO components on plasma lipid contents in hyperlipidemic rats.
Rat Group
MGO Plasma lipid (A) (B) (C) Percent
component content Placebo +Triton WR-1339 +MGO component change
(mg/dl) +Triton WR-1339
a-pinene Total cholesterol 69.066.0 354.0627.7 350.6638.1
ns 21.0
a-pinene LDL-cholesterol 13.662.7 130.6613.6 134.0617.6
ns +2.6
a-pinene Triglycerides 130.4620.8 2067.66295.3 2082.76376.2
ns +0.7
b-pinene Total cholesterol 69.066.0 354.0627.7 346.1621.0
ns 22.3
b-pinene LDL-cholesterol 13.662.7 130.6613.6 130.5616.2
ns 20.1
b-pinene Triglycerides 130.4620.8 2067.66295.3 1930.76252.8
ns 26.6
myrcene Total cholesterol 69.565.1 335.0625.4 333.6633.5
ns 20.4
myrcene LDL-cholesterol 12.862.3 97.1616.4 95.9617.2
ns 22.1
myrcene Triglycerides 132.5611.0 2186.46363.1 2147.96398.5
ns 21.7
b-caryophyllene Total cholesterol 69.565.1 335.0625.4 329.6624.9
ns 21.6
b-caryophyllene LDL-cholesterol 12.862.3 97.1616.4 97.1612.9
ns 20.3
b-caryophyllene Triglycerides 132.5611.0 2186.46363.1 2078.56353.7
ns 24.9
linalool Total cholesterol 69.565.1 335.0625.4 339.4629.3
ns +1.3
linalool LDL-cholesterol 12.862.3 97.1616.4 102.4613.0
ns +6.1
linalool Triglycerides 132.5611.0 2186.46363.1 2184.86384.7
ns 20.1
camphene Total cholesterol 68.3612.9 280.4621.5 226.0618.5
*** 219.4
camphene LDL-cholesterol 12.963.4 49.466.1 36.466.8
** 226.3
camphene Triglycerides 124.5628.0 1920.56197.8 1481.56219.5
*** 222.9
The placebo group (A) was administered 1 ml carrier alone, whereas, the Triton WR-1339 group (B) was administered 1 ml carrier and one h later 1 ml of Triton WR-1339
(200 mg/kg of body weight). The rats in group (C) were treated with various MGO components and one h later were treated with Triton WR-1339. Each MGO-
component was administered at a dose identical to that contained in the 4% dose of MGO. Twenty-four h later, blood was collected from the hearts of animals in
heparinized tubes, and plasma samples were prepared and assayed for total cholesterol, LDL-cholesterol, and triglycerides. The percent change caused by the various
MGO components (C) is expressed relative to the group of Triton WR-1339-treated rats (B), which was taken as 100%. The values represent mean 6 SD of six rats. Values
of camphene treated rats were significantly different as compared to Triton WR-1339 treated rats with p,0.01 (**) and p,0.001 (***) by the Student-Newmann-Keuls
test. Values of a-pinene, b-pinene, myrcene, b-caryophyllene and linalool treated rats vs Triton WR-1339 treated rats were non significant, ns (p.0.05).
doi:10.1371/journal.pone.0020516.t003
Table 4. The anti-hyperlipidemic action of MGO is associated with camphene.
Rat Group Percent change
Plasma lipid (A) (B) (C) (D) +Mixture
content (mg/dl) Placebo Triton WR-1339 +Mixture A +Mixture B AB
+Triton WR-1339 +Triton WR-1339
Total cholesterol 65.166.9 262.9632.3 263.4623.7
ns 156.7612.3
*** +1.2 240.4
LDL-cholesterol 16.462.8 47.669.1 45.4610.7
ns 18.562.7
*** 24.7 261.1
Triglycerides 130.2622.6 1950.86191.1 19766140.7
ns 888.7699.3
*** +1.3 254.4
The placebo group (A) was administered 1 ml carrier alone. The Triton WR-1339 group (B) was administered 1 ml carrier and one h later 1 ml of Triton WR-1339
(200 mg/kg). Animals in (C) and (D) received Mixture A and Mixture B, respectively, in 1 ml carrier and one hour later received Triton WR-1339. Mixture A consisted of a-
pinene, b-pinene, myrcene, b-caryophyllene and linalool; and Mixture B consisted of Mixture A+camphene. The constituents in Mixtures A and B were present at
concentrations identical to those contained in the 4% MGO dose. The percent change caused by Mixture A and B treatments is expressed relative to measurement in
the group of Triton WR-1339-treated rats (B), which was defined as 100%. The values represent mean 6 SD of six rats. Significantly different values were obtained in
Mixture B-treated rats compared to Triton WR-1339-treated rats with p,0.001 (***) by the Student-Newmann-Keuls test. Values of Mixture A-treated rats vs Triton WR-
1339-treated rats were non significant, ns (p.0.05).
doi:10.1371/journal.pone.0020516.t004
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33.4% (p,0.001), respectively (Figure 1). It should be noted that
the average cholesterol content was 4.774+0.883 mg/mg of total
protein in control cells. In the 1 h incubation period, camphene
exhibited a more dramatic effect than mevinolin, whereas after
18 h of incubation, the effect of mevinolin was increased, while
camphene had no significant further effect.
Camphene acts independently of HMG-CoA reductase
activity
In order to investigate whether the camphene-induced anti-
hyperlipidemic activity was dependent on HMG-CoA reductase,
the enzyme activity was determined in HepG2 cells extracts. The
effect of camphene on HMG-CoA reductase activity was also
compared with the mevinolin-induced effect. Changes in HMG-
CoA reductase activity were monitored by determining the
incorporation of [
14C]HMG-CoA into mevalonate. Cells were
incubated for 18 h in the presence of camphene (37 mM) and
mevinolin (37 mM), and cell extracts were prepared and assayed
for HMG-CoA reductase activity as described in the Methods
section. As shown in Figure 2, mevinolin treatment caused a 3-fold
increase in HMG-CoA reductase activity as compared to
untreated cells (p,0.001). In contrast, camphene treatment
resulted in negligible changes in HMG-CoA reductase activity
(115% of control, p.0.05). These results indicated that camphene
exhibited a cholesterol-lowering activity via a process independent
of inhibition of HMG-CoA reductase. Apparently, the cholesterol-
lowering ability of camphene is mediated via a novel metabolic
process distinctly different than the process of inhibition of HMG-
CoA reductase induced by mevinolin.
Effect of camphene on intracellular cholesterol ester content
To further examine the effect of camphene, cholesterol ester
levels were determined. HepG2 cells were incubated with
camphene (37 mM) and mevinolin (37 mM) for a period of 1 h
and 18 h. Subsequently, lipids were extracted and cholesterol
esters were separated by TLC and measured by gas chromatog-
raphy. Incubation of HepG2 cells with camphene significantly
decreased cholesterol ester concentration by 24% (p,0.01) as
compared to the control (Figure 3). As shown in this Figure,
treatment for 1 h with camphene and mevinolin led to a
significant decrease in the cholesterol ester concentration as
compared to untreated cells. Treatment with camphene for 18 h
significantly decreased intracellular cholesterol ester by 7.7%
(p,0.01) compared to cholesterol ester levels in control cells
(Figure 3). Incubation with mevinolin for 18 h resulted in a
decrease of 22% (p,0.001). Mevinolin treatment had a different
effect than the camphene-induced effect, implying that mevinolin
may have higher bioavailability.
Proliferation and protein content of treated HepG2 cells
We investigated whether the hypolipidemic effects of camphene
and mevinolin were associated with changes in cell proliferation
and protein content. Treatment of HepG2 cells with camphene
and mevinolin for various times ranging from 4 h to 24 h showed
no significant effect on the cell number as determined by the
Trypan blue method (results not shown). Moreover, camphene
was shown to suppress hyperlipidemia without affecting the global
cell protein content in the in vitro HepG2 cell model (Table 6).
Camphene was also confirmed to have no significant effect on cell
proliferation as measured by the MTT cell growth assay method
(Table 7), suggesting that camphene is no cytotoxic under the
present experimental conditions.
Discussion
Disorders of lipid metabolism are the primary risk factor for
cardiovascular disease. The known lipid-lowering drugs (statins,
fibrates, bile acid sequestrants, etc) regulate the lipid metabolism
Table 5. Effect of various camphene concentrations on contents of total cholesterol, LDL- cholesterol and triglycerides in the
plasma of Triton WR-1339-treated rats.
Rat Group
Camphene Plasma lipid (A) (B) (C) Lipid decrease
dose per content (mg/dl) Placebo +Triton WR-1339 +camphene in rat group (C)
body weight +Triton WR-1339 compared to
(mg/g) rat group (B) (%)
1.5 Total cholesterol 68.3612.9 280.4621.5 226.0618.5
*** 19.4
1.5 LDL-cholesterol 12.963.4 49.466.1 36.466.8
** 26.3
1.5 Triglycerides 124.5628.0 1920.56197.8 1481.56219.5
*** 22.9
7.5 Total cholesterol 70.366.2 342.1627.6 231.2616.1
*** 32.4
7.5 LDL-cholesterol 14.262.8 99.2611.8 53.767.1
*** 45.9
7.5 Triglycerides 136.4613.9 2875.06180.7 2042.36153.4
*** 29.0
30 Total cholesterol 72.069.1 529.1685.8 240.8622.5
*** 54.5
30 LDL-cholesterol 13.263.1 284.5639.9 131.169.4
*** 54.0
30 Triglycerides 120.5615.5 2443.66126.0 1600.3620.3
*** 34.5
The placebo group (A) was administered 1 ml carrier alone, whereas the Triton WR-1339 group (B) was administered 1 ml carrier and one h later 1 ml of Triton WR-1339
(200 mg/kg). The camphene treated group (C) received a dose of camphene and one h later a single dose of Triton WR-1339. Camphene was administered at 1.5, 7.5
and 30 mg/g of body weight. Controls and camphene were injected ip. Twenty-four hours later, blood was collected from the hearts of animals in heparinized tubes,
and plasma samples were prepared and assayed for total cholesterol, LDL-cholesterol, and triglycerides. The values represent mean 6 SD of six rats. Significantly
different lipid contents were determined in the camphene treated rats (C) compared to rats treated with Triton WR-1339 alone (B). p,0.01 (**), and p,0.001 (***) by the
Student-Newmann-Keuls test.
doi:10.1371/journal.pone.0020516.t005
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[55–57]. Therefore, various pharmacologically active molecules
are under intensive investigation in order to find new therapies for
dislipidemia [58,59]. Lately, the protective effect of chios mastic
gum against LDL oxidation was well documented as it was shown
that triterpenes present in MG-derived essential oil exhibit
antioxidant/antiatherogenic effect on LDL [30,60]. Moreover,
several studies using an aqueous extract from P.lentiscus leaves and
MG powder have shown a strong hepatoprotective effect in rats
and in humans [61,62]. In addition, MG powder could have a
cardioprotective role in humans without any substantial adverse
effects in humans and animals [63,64]. In the present study, the
activity of MGO and camphene on plasma cholesterol and
triglyceride levels was investigated in a rat model in which the
circulating levels of total cholesterol, LDL-cholesterol and
triglycerides were substantially increased by administration of
the detergent, Triton WR-1339. This compound inhibits lipopro-
tein lipase resulting in increased cholesterol and triglycerides levels
in plasma and thus it has been widely used for induction of acute
hyperlipidemia [65] and for assay of putative hypocholesterolemic
drugs [52,66–68]. Initially, the effect of MGO was examined in
naı ¨ve rats. In these animals, MGO drastically reduced plasma
cholesterol and triglyceride levels (Table 1). Furthermore, a similar
effect was observed when the animals were injected with MGO
prior to induction of hyperlipidemia with Triton WR-1339
(Table 2). MG has already been associated with cardiovascular
protection by inhibiting human LDL oxidation [30] and because
of the presence of triterpenes causing an antioxidant/antiathero-
genic effect [60]. Moreover, a beneficial action of MG powder was
observed on serum total and LDL-cholesterol in healthy human
subjects [62].
The chemical composition of MGO has been analysed but as
yet no correlation has been made between the hypolipidemic
activity with anyone of its individual constituents. In this study, we
have shown for the first time that the hypolipidemic activity of
MGO is associated with one of its constituents, namely camphene.
Interestingly, camphene represents only a minor constituent
(0.83%) of MGO [42]. Treatment with camphene alone revealed
that cholesterol and triglyceride levels were inhibited less than with
MGO administration (Tables 2 and 3). Moreover, a higher dose of
camphene was required to achieve the same hypolipidemic effect
as MGO (Table 5). This result was attributed to the potential
synergistic action between camphene and other MGO compo-
nent(s). However, when camphene was administered with each
one of the major MGO individual components, no further
decrease in cholesterol and triglyceride levels was observed (data
not shown). On the other hand, the hypolidemic effect was
restored to almost the same level obtained with MGO when
camphene was used in combination with all the 5 major
constituents of MGO (Table 4), implying a synergism among all
these constituents. Camphene is a bicyclic monoterpene and a
constituent of many essential oils derived from various plants [69–
73]. It is used as a food additive for artificial flavoring as well as in
the preparation of fragrances and in the manufacture of synthetic
Figure 1. Effect of camphene and mevinolin on cholesterol
levels in HepG2 cells. On day 7 (see Methods), HepG2 cells were
incubated with camphene (37 mM) and mevinolin (37 mM) for 1 h and
18 h. Cholesterol was extracted and quantified by gas chromatography.
The cholesterol concentration in treated cells was plotted relative to the
concentration in untreated control cells (100%). Results are from three
independent experiments in triplicates and expressed as the mean 6
SD. p,0.05 (*); p,0.01 (**); and p,0.001 (***) by the Student-
Newmann-Keuls test.
doi:10.1371/journal.pone.0020516.g001
Figure 2. Effect of camphene and mevinolin on HMG-CoA
reductase activity in HepG2 cells. On day 7, HepG2 cells were
incubated with camphene (37 mM) and mevinolin (37 mM) for 18 h.
After incubation, cell extracts were prepared and assayed for HMG-CoA
reductase activity as described in the Methods section. HMG-CoA
reductase activity is expressed in cpm. Results are from three
independent experiments in triplicates and expressed as the mean 6
SD. Significant differences between values were determined by the
Student-Newmann-Keuls test. p,0.001 (***) and ns (non significant).
doi:10.1371/journal.pone.0020516.g002
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protective effect against oxidative stress [75].
To gain some insights about the mechanism of action of
camphene hypolipidemic activity, we investigated its effect on
HMG-CoA reductase activity in HepG2 cells. It is well known that
statins decrease total, free and esterified cholesterol concentrations
in HepG2 cells [76,77] by directly inhibiting HMG-CoA
reductase. We showed that camphene did not significantly
inhibited HMG-CoA reductase activity (Figure 2), implying that
its hypolipidenic activity is via an unidentified yet mechanism
different than that utilized by statins. Although, camphene
treatment had no effect on HMG-CoA reductase activity, a
decrease in free cholesterol and cholesterol ester levels was
observed (Figures 1 and 3).
It should be noted that camphene is a monoterpene present in
several essential oils derived from plants of diverse species. In
plants, monoterpenes are products of the isoprenoid biosynthetic
pathway. It was previously shown that only cyclic monoterpenes in
which oxygen is a substituent have the capacity to inhibit hepatic
HMG-CoA reductase activity, whereas pinene and camphene that
contain no oxygen substituents had no significant effect [78]. It
appears that the oxy- and hydroxy- substituted cyclic monoter-
penes act in a similar manner as the oxy-substituents of cholesterol
such as 25-hydroxy cholesterol that is far more potent inhibitor
than cholesterol itself [79].
In our rat model, Triton WR-1339 acts as a surfactant and
suppresses the action of lipases to block the uptake of lipoproteins
from circulation by extra-hepatic tissues, resulting in increased
blood lipid concentration [52,65]. Therefore, the lipid-lowering
effect caused by the administration of camphene may be due to
reactivation of lipolytic enzymes for early clearance of lipids from
circulation in Triton-induced hyperlipidemia. The observation
that administration of MGO in naı ¨ve rats led to the same
reduction in their plasma total cholesterol, LDL-cholesterol and
triglyceride levels, implies that camphene may act as an LPL
activator. Previous studies have shown that compounds that
increase LPL activity decrease plasma cholesterol and triglyceride
levels contributing to an antiatherogenic effect [80]. Further, the
fact that camphene acts independent of HMG-CoA reductase
would allow its use not only as a single agent, but also in
combination with statins, the most widely prescribed class of drugs
for lowering cholesterol according to the American Heart
Association. A suggested combined treatment with camphene
and a statin would allow the use of low doses of statin, which is
known to occasionally result to liver injury and often in patient
non-compliance. Alternatively, it would be possible to use
camphene with plant-derived stanol and sterol esters, which are
compounds that competitively inhibit the absorption of cholesterol
Figure 3. Effect of camphene and mevinolin on cholesterol
ester contents in HepG2 cells. On day 7, HepG2 cells were
incubated with camphene (37 mM) and mevinolin (37 mM) for 1 h and
18 h. Lipids were extracted and separated by TLC. Cholesterol ester
contents were quantified by gas chromatography. Cholesterol ester
concentrations in untreated cells (control) were defined as 100% and
the levels in treated cells were plotted relative to that value. Results are
from three independent experiments performed in triplicates and
expressed as the mean 6 SD. p,0.05 (*); p,0.01 (**); p,0.001 (***) by
the Student-Newmann-Keuls test.
doi:10.1371/journal.pone.0020516.g003
Table 6. Effect of MGO and camphene on whole protein
content of HepG2 cells.
Protein (mg/ml)




On day 7 (see Methods), identical cultures of HepG2 cells were incubated with
camphene (37 mM) and mevinolin (37 mM) for 1 h and 18 h, and subsequently
whole cell protein was quantified. The measurements shown were obtained
from three independent experiments performed in triplicate and expressed as
the mean values 6 SD. p.0.05 by the Student-Newmann-Keuls test.
doi:10.1371/journal.pone.0020516.t006
Table 7. Cytotoxicity of camphene.
Treatment MTT (% of control)
control 100
camphene 25 mM 99.5760.74
camphene 50 mM 98.8762.15
camphene 100 mM 98.0562.3
Confluent HepG2 cells were exposed to various concentrations of camphene
(25, 50 and 100 mM) for 24 h and cytotoxicity was determined with the MTT
assay (Methods section). The measurements shown were obtained from three
independent experiments performed in triplicate and expressed as the mean
values 6 SD. p.0.05 by the Student-Newmann-Keuls test.
doi:10.1371/journal.pone.0020516.t007
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synthetically prepared from a-pinene (CAS No. 79-92-5: Screen-
ing information Data Set (SIDS) of OECD High Volume
Chemicals Programme, 1993). Taken together the hypolipidemic
activity of camphene and the readiness to manufacture this
monoterpene, we propose that camphene could develop to an
alternative hypolipidemic drug. In conclusion, further investiga-
tions are warranted for the development of camphene as a
hypolipidemic agent.
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